The DOI matches its Crossref record; 40 of the 46 references it cites were found in a registry or an index; 3 of the 20 sources its claims cite were checked for support.
Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents
Open accessAbstract
Bacopa monnieri and the constituents of this plant, especially bacosides, possess various neuropharmacological properties. Like drugs, some herbal extracts and the constituents of their extracts alter cytochrome P450 (CYP) enzymes, causing potential herb-drug interactions. The effects of Bacopa monnieri standardized extract and the bacosides from the extract on five major CYP isoforms in vitro were analyzed using a luminescent CYP recombinant human enzyme assay. B. monnieri extract exhibited non-competitive inhibition of CYP2C19 (IC50/Ki = 23.67/9.5 µg/mL), CYP2C9 (36.49/12.5 µg/mL), CYP1A2 (52.20/25.1 µg/mL); competitive inhibition of CYP3A4 (83.95/14.5 µg/mL) and weak inhibition of CYP2D6 (IC50 = 2061.50 µg/mL). However, the bacosides showed negligible inhibition of the same isoforms. B. monnieri, which is orally administered, has a higher concentration in the gut than the liver; therefore, this herb could exhibit stronger inhibition of intestinal CYPs than hepatic CYPs. At an estimated gut concentration of 600 µg/mL (based on a daily dosage of 300 mg/day), B. monnieri reduced the catalytic activities of CYP3A4, CYP2C9 and CYP2C19 to less than 10% compared to the total activity (without inhibitor = 100%). These findings suggest that B. monnieri extract could contribute to herb-drug interactions when orally co-administered with drugs metabolized by CYP1A2, CYP3A4, CYP2C9 and CYP2C19.
Overview
CoChat Summary
TL;DR
Bacopa monnieri standardized extract inhibited several human CYP enzymes in vitro, most potently CYP2C19, while its bacoside constituents showed negligible inhibition. The authors suggest possible pre-systemic herb-drug interactions, especially via intestinal CYP3A4, CYP2C9, and CYP2C19 at estimated gut concentrations.
Key findings
- B. monnieri extract showed moderate inhibition of CYP2C19 (IC50/Ki = 23.67/9.5 µg/mL), CYP2C9 (36.49/12.5 µg/mL), CYP1A2 (52.20/25.1 µg/mL), and CYP3A4 (83.95/14.5 µg/mL), with weak inhibition of CYP2D6 (IC50 = 2061.50 µg/mL).
- Inhibition modes were non-competitive for CYP2C19, CYP2C9, and CYP1A2, and competitive for CYP3A4.
- Bacoside A, bacoside A3, bacopaside II, bacopaside X, bacopasaponin C, and bacopaside I showed negligible inhibition of all five CYP isoforms at concentrations up to 100 µM.
- At an estimated gut concentration of 600 µg/mL based on 300 mg/day and 500 mL intestinal volume, B. monnieri extract reduced CYP3A4, CYP2C9, and CYP2C19 activities to 4.1%, 4.9%, and 7.9% of total activity, respectively.
Methods
- In vitro luminescent CYP recombinant human enzyme assay (P450-Glo™) using CYP1A2, CYP3A4, CYP2C9, CYP2C19, and CYP2D6.
- B. monnieri extract was tested at 0.01–1000 µg/mL; bacosides and positive controls at 0.01–100 µM; all dissolved in DMSO with organic solvent kept below 0.25% (v/v).
- IC50 values were calculated by non-linear regression; Ki values and inhibition modes were determined using Lineweaver-Burk plots and secondary plots of slopes versus extract concentration.
Limitations
- The paper states that the compounds responsible for CYP inhibition by B. monnieri extract remain unknown and require further work.
- The paper states that further in vivo investigation of drug-herb interactions between B. monnieri extracts and relevant drugs may be important.
- Evident from the text: findings are from in vitro recombinant enzyme assays, and the estimated gut concentration and projected intestinal CYP activity are theoretical, based on a daily dose of 300 mg/day and an assumed 500 mL intestinal volume, without clinical confirmation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
3 Valid · 0 Not valid · 9 Not checked · 23 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Therefore, the concomitant use of B. monnieri with clinically prescribed drugs that are substrates of CYP3A4, CYP2C9, and CYP2C19 isoforms, particularly those exhibiting poor bioavailability due to extensive metabolism such as clozapine [31] and midazolam [32] could cause potential herb-drug interactions.”
§ Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents > 3. Discussion
What the sources say
- Not checked — no full text of the sourcecites [31] Linnet, 1997, Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes, Drug. Metab. Dispos.
- Supportedcites [32] Riss, 2008, Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics, Acta Neurol. Scand. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At this concentration, B. monnieri extract may potentially reduce the catalytic activities of CYP3A4, CYP2C9 and CYP2C19 to less than 10% of the total CYP activity (without any inhibition ~100%, from Figure 2).”
§ Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents > 2. Results > 2.1. The Determination of the Apparent Half-Maximal Inhibitory Concentration (IC50) for Test Samples and Standard Inhibitors
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, all of the constituents, bacoside A, bacoside A3, bacopaside II, bacopaside X, bacopasaponin C and bacopaside I at concentrations up to 100 µM, showed negligible inhibition towards the five CYP enzymes (Table 1).”
§ Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents > 2. Results > 2.1. The Determination of the Apparent Half-Maximal Inhibitory Concentration (IC50) for Test Samples and Standard Inhibitors
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Lineweaver-Burk double reciprocal plot shows that B. monnieri extract non-competitively inhibited CYP1A2, CYP2C9 and CYP2C19 activity and competitively inhibited CYP3A4 activity (Figure 3).”
- Also stated in: § 2.2. Determination of the Inhibition Constant (Ki) Values and the Modes of Inhibition of B. monnieri Extract · plain
“The secondary plots based on the slope of Lineweaver-Burk plots show that the Ki values for CYP1A2, CYP3A4, CYP2C9 and CYP2C19 are of 25.1, 14.5, 12.5, and 9.5 μg/mL, respectively (Figure 4).”
§ Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents > 2. Results > 2.2. Determination of the Inhibition Constant (Ki) Values and the Modes of Inhibition of B. monnieri Extract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2.2. Determination of the Inhibition Constant (Ki) Values and the Modes of Inhibition of B. monnieri Extract · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings suggest that B. monnieri extract could contribute to herb-drug interactions when orally co-administered with drugs metabolized by CYP1A2, CYP3A4, CYP2C9 and CYP2C19.”
§ Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents > Abstract
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
6 more claims
Create a free account to see all 35 claims and every source verdict.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 14
- The quote only partly states this claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, we hypothesize that our patient’s symptomatology is consistent with a potential cholinergic toxicity due to the effect of B. monnieri extract on CYP isoforms that metabolize cevimeline, resulting in elevated therapeutic concentrations of plasma cevimeline.”
From Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“both of which are responsible for metabolizing a majority of drugs in humans.”
From Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It has been previously demonstrated that B. monnieri alters cytochrome P450 enzymes.”
From Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“A study of the effect of B. monnieri on the five major CYP isoforms in vitro demonstrated that B. monnieri acts as a competitive inhibitor of CYP3A4 and a weak inhibitor of CYP2D6 [10]”
From Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report (2022) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents > 3. Discussion
“The pharmacokinetic parameters (IC50, Ki values) show that B. monnieri extract most strongly inhibits CYP2C19 followed by CYP2C9, CYP1A2, and CYP3A4 and most weakly inhibits CYP2D6.”
§ Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents > 2. Results > 2.2. Determination of the Inhibition Constant (Ki) Values and the Modes of Inhibition of B. monnieri Extract
“| CYP1A2 | 25.1 | Non-competitive | | CYP3A4 | 14.5 | Competitive |”
Citations
Cites
(2007) · PubMed · Cited by 953
THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008672 · Cited by 870 · cited 1×
“[17], and CYP3A4 was found to be the most abundant CYP enzyme (~80%), followed by CYP2C9 (~15%), CYP2C19 (2%), CYP2J2 (<2%) and”
BackgroundPolymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
Ingelman-Sundberg, M., Oscarson, M., & McLellan, R. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01363-2 · Cited by 539 · cited 1×
“Furthermore, CYP2C19 and CYP2C9 exhibit genetic polymorphisms [39].”
BackgroundBenzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511 · cited 1×
“monnieri with clinically prescribed drugs that are substrates of CYP3A4, CYP2C9, and CYP2C19 isoforms, particularly those exhibiting poor bioavailability due to extensive metabolism such as clozapine [31] and midazolam [32] could cause potential herb-drug interactions.”
BackgroundBacopa monniera, a reputed nootropic plant: An overview
Russo, A., & Borrelli, F. (2005) · Phytomedicine · doi:10.1016/j.phymed.2003.12.008 · Cited by 447 · cited 3×
“A reputable nootropic agent and the second most highly touted herb in Ayurveda [10,11], B.”
BackgroundExtrahepatic Metabolism of Drugs in Humans
Krishna, D. R., & Klotz, U. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426020-00007 · Cited by 437 · cited 1×
“CYPs are also expressed in extrahepatic tissues, such as the intestinal mucosa, kidneys, lungs, skin and brain [15].”
BackgroundJordan, S. A., Cunningham, D. G., & Marles, R. J. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.005 · Cited by 415 · cited 1×
“monnieri products are classified as herbal or natural products, and in most countries, the regulatory requirements to market natural products are less stringent compared to conventional drugs because natural products are considered to be low risk products [19].”
BackgroundC., S., P., N., J., L., J., C., C., H., L., D., & T., R. (2001) · Psychopharmacology · doi:10.1007/s002130100815 · Cited by 342 · cited 3×
“These traditional claims have been supported by several preclinical and clinical studies [2–5], and the observed cognitive effects have been attributed to bacoside A [6–8], which is a mixture of four triglycosidic saponins (bacoside A3, bacopaside II, bacopaside X and bacopasaponin C) [9].”
BackgroundMethodChronic Effects of Brahmi (Bacopa monnieri) on Human Memory
Roodenrys, S. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00419-5 · Cited by 313 · cited 3×
“These traditional claims have been supported by several preclinical and clinical studies [2–5], and the observed cognitive effects have been attributed to bacoside A [6–8], which is a mixture of four triglycosidic saponins (bacoside A3, bacopaside II, bacopaside X and bacopasaponin C) [9].”
BackgroundMethodCalabrese, C., Gregory, W. L., Leo, M., Kraemer, D., Bone, K., & Oken, B. (2008) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2008.0018 · Cited by 301 · cited 1×
“promising results in clinical trials [4,5] should also be tested for herb-drug interactions before the extracts are marketed for therapeutic use.”
Background
Research works printed but not linked: 2
- Tyagi, 2010, Herb-drug interactions: Emerging threat and their management, Bot. Res. Int., 3, 1
- Gunaratna, 2009, Drug metabolism & pharmacokinetics in drug discovery: A primer for bioanalytical chemists, part I, Curr. Sep., 19, 17
Cited by
Ramasamy, S., Chin, S. P., Sukumaran, S. D., Buckle, M. J. C., Kiew, L. V., & Chung, L. Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126565 · Cited by 100
“monnieri extracts inhibit some human cytochrome P450 (CYP) drug metabolizing enzymes [16].”
BackgroundSelf-citationBacopa monnieri as an Antioxidant Therapy to Reduce Oxidative Stress in the Aging Brain
Simpson, T. N., Pase, M. P., & Stough, C. K. K. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/615384 · Cited by 133
“Some of the chemical constituents of EBm are lipophilic [79, 80].”
Elias, R., Benhamou, R. I., Jaber, Q. Z., Dorot, O., Zada, S. L., Oved, K., Pichinuk, E., & Fridman, M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.003 · Cited by 78
Interactions between clopidogrel and traditional Chinese medicine
Hu, Y., & Wang, J. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01945-3 · Cited by 48
Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions
Wang, K., Gao, Q., Zhang, T., Rao, J., Ding, L., & Qiu, F. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1758714 · Cited by 44
“…natural compounds andherbal supplement extracts have shown that CYP2C9 can be subject to different types of inhibition, including competitive, noncompetitive, mixed-model, and mechanism-based (irreversible) inhibition (Obach 2000; Ramasamy et al. 2014; Wang et al. 2015; Chiangsom et al. 2016).”
Background
Metadata
- Authors
- Ramasamy, S., Kiew, L., & Chung, L.
- Affiliations
- University of Malaya (MY)
- Corresponding author
- Chung, Lip
- ORCID
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2014-02-24
- Volume
- 19
- Issue
- 2
- Pages
- 2588-2601
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6271976
- OpenAlex
- W1977728948
- Cited by
- 47
- References
- 46
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 5 · 2019: 6 · 2018: 1 · 2017: 2 · 2016: 5 · 2015: 6 · 2014: 3
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Universiti Malaya
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Keywords
- Bacopa monnieri, bacosides, cytochrome P450 inhibition, herb-drug interactions, CYP3A4, CYP2C19, CYP2C9, CYP1A2, CYP2D6, standardized herbal extract, intestinal drug metabolism
- MeSH terms
- Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 Enzyme System, Humans, Inactivation, Metabolic, Microsomes, Liver, Plant Extracts, Saponins, Triterpenes, Cytochrome P-450 CYP1A2, Cytochrome P-450 CYP2D6, Bacopa, Herb-Drug Interactions, Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP2C19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents. https://app.cochat.ai/papers/10.3390/molecules19022588
- The paper
- Ramasamy, S., Kiew, L., & Chung, L. (2014). Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents. Molecules. https://doi.org/10.3390/molecules19022588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.